ArticleOphthalmology and therapy2025
Intraocular Pressure Trends in Children with Myopia Receiving Atropine Therapy.
Article in Ophthalmology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Ocular Surface Outcomes with Different 0.05% Atropine Dosing Frequencies in Children with Myopia: A Secondary Analysis of a Randomized Trial.Ophthalmology and therapy · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionTopical atropine is widely used for myopia control in children, with proven efficacy in slowing myopia progression. However, concerns remain regarding its potential effects on intraocular pressure (IOP), particularly with long-term use. This study aimed to evaluate the longitudinal effects of topical atropine on IOP in children with myopia.
methodsThis retrospective, longitudinal study enrolled children using 0.125% atropine to control myopia progression and atropine non-users. IOP was measured repeatedly before and during treatment. RTVue optical coherence tomography (OCT) measured retinal nerve fiber layer (RNFL) and ganglion cell complex (GCC) thickness. Multilevel models assessed IOP changes by adjusting age, sex, spherical equivalent, central corneal thickness, and baseline IOP.
resultsA total of 188 patients (376 eyes) in the atropine group and 188 patients (376 eyes) in the control group were included. There were 86 boys (46%) aged 8.0 ± 2.5 years. Patients in the atropine group were more myopic (-1.17 ± 1.40 versus 0.73 ± 1.83 D, P < 0.001). The central corneal thickness and baseline IOP (atropine: 17.6 ± 3.0 mmHg; control: 17.2 ± 3.6 mmHg) were similar. Over a follow-up of 18.6 months (atropine, 19.3 months; control, 18.0 months), the final IOP was higher in the atropine group (18.3 ± 3.6 versus 16.7 ± 3.2 mmHg, P < 0.001). In the multivariable multilevel models, atropine was associated with an additional 0.51-mmHg increase (95% confidence interval [CI] 0.36-0.67, P = 0.001) in IOP per year when adjusted for sex, age, central corneal thickness, spherical equivalent, and baseline IOP. RNFL (104.0 ± 8.8 versus 102.6 ± 7.5 µm, P = 0.475) and GCC thickness (98.1 ± 5.6 versus 96.7 ± 5.8 µm, P = 0.270) showed no significant differences between groups.
conclusionsAtropine use for myopia control in children was associated with a modest IOP increase without apparent impact on RNFL. Regular IOP monitoring is advisable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.